Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 45, Issue 7, 2017, Pages 933-940

  Yarur, A J ^a   Kanagala, V ^a   Stein, D J ^a   Czul, F ^b   Quintero, M A ^b   Agrawal, D ^a   Patel, A ^a   Best, K ^a   Fox, C ^a   Idstein, K ^a   Abreu, M T ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB;

ADULT; ANUS FISTULA; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE ACTIVITY; DRUG DOSE ESCALATION; FEMALE; HEALING; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; BLOOD; DOSE RESPONSE; DRUG EFFECTS; MIDDLE AGED; RECTAL FISTULA; WOUND HEALING; YOUNG ADULT;

ADULT; CROHN DISEASE; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; RECTAL FISTULA; TREATMENT OUTCOME; WOUND HEALING; YOUNG ADULT;

EID: 85013449857     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13970     Document Type: Article

References (18)

1. SchwartzDA, LoftusEVJr, TremaineWJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002; 122: 875–80.
2. MakowiecF, JehleEC, StarlingerM. Clinical course of perianal fistulas in Crohn's disease. Gut 1995; 37: 696–701.
3. TozerPJ, BurlingD, GuptaA, PhillipsRKS, HartAL. Review article: medical, surgical and radiological management of perianal Crohn's fistulas. Aliment Pharmacol Ther 2010; 33: 5–22.
4. PresentDH, RutgeertsP, TarganS, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398–405.
5. SandsBE, AndersonFH, BernsteinCN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876–85.
6. MaserEA, VillelaR, SilverbergMS, GreenbergGR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1248–54.
7. UngarB, LevyI, YavneY, et al. Optimizing anti-TNF-α therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2016; 14: 550–2.
8. YarurAJ, KubiliunMJ, CzulF, et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol 2015; 13: 1118–1124.
9. ChaparroM, GuerraI, Muñoz-LinaresP, GisbertJP. Systematic review: antibodies and anti-TNF-α levels in inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 971–86.
10. BillietT, CleynenI, BalletV, et al. Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experience. Aliment Pharmacol Ther 2016; 44: 673–83.
11. SilverbergMS, SatsangiJ, AhmadT, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19(Suppl A): 5–36.
12. WangS-L, OhrmundL, HauensteinS, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods 2012; 382: 177–88.
13. SandbornWJ, PresentDH, IsaacsKL, et al. Tacrolimus for the treatment of fistulas in patients with crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 2003; 125: 380–8.
14. Martínez-BorraJ, López-LarreaC, GonzálezS, et al. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol 2002; 97: 2350–6.
15. DavidovY, UngarB, Bar-YosephH, et al. Association of induction infliximab levels with clinical response in perianal Crohn's disease. J Crohns Colitis 2016; doi: 10.1093/ecco-jcc/jjw182
16. BaertF, NomanM, VermeireS, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601–8.
17. VandeCasteele N, KhannaR, LevesqueBG, et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut 2015; 64: 1539–45.
18. YarurAJ, JainA, SussmanDA, et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut 2016; 65: 249–55.